Compare · LLY vs NVCT
LLY vs NVCT
Side-by-side comparison of Eli Lilly and Company (LLY) and Nuvectis Pharma Inc. (NVCT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and NVCT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY carries a market cap of $234.46B.
- Over the past year, LLY is up 0.8% and NVCT is down 17.0% - LLY leads by 17.8 points.
- LLY has hit the wire 10 times in the past 4 weeks while NVCT has been quiet.
- LLY has more recent analyst coverage (25 ratings vs 4 for NVCT).
- Company
- Eli Lilly and Company
- Nuvectis Pharma Inc.
- Price
- $884.02-3.63%
- $8.89+2.48%
- Market cap
- $234.46B
- -
- 1M return
- -3.48%
- +11.40%
- 1Y return
- +0.77%
- -17.02%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 10
- 0
- Recent ratings
- 25
- 4
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Nuvectis Pharma Inc.
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Latest LLY
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 4 filed by Sulzberger Gabrielle
- SEC Form 4 filed by Luciano Juan R
- SEC Form 4 filed by Fyrwald J Erik
- SEC Form 4 filed by Alvarez Ralph
- Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies
- Lilly confirms date and conference call for first-quarter 2026 financial results announcement
- ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
- Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL
- Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.
Latest NVCT
- Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
- SEC Form EFFECT filed by Nuvectis Pharma Inc.
- SEC Form S-3 filed by Nuvectis Pharma Inc.
- Nuvectis Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-K filed by Nuvectis Pharma Inc.
- Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
- Chief Dev. & Ops. Officer Shemesh Shay was granted 150,000 shares, increasing direct ownership by 9% to 1,793,068 units (SEC Form 4)
- Chairman & CEO Bentsur Ron was granted 150,000 shares, increasing direct ownership by 4% to 3,675,924 units (SEC Form 4)
- Chief Science & Business Off Poradosu Enrique was granted 150,000 shares, increasing direct ownership by 9% to 1,806,319 units (SEC Form 4)
- Vice President, Finance Carson Michael J. was granted 61,200 shares, increasing direct ownership by 44% to 200,118 units (SEC Form 4)